Current status of imipenem-resistant Pseudomonas aeruginosa infection and analysis of drug resistance

OBJECTIVE To investigate the infection status and drug resistance of imipenem-resistant Pseudomonas aeruginosa(PAE) causing nosocomial infections,to provide the scientific evidence for rational clinical application of the antibiotics. METHODS From Jan.2008 to Dec.2010,the status and drug resistance of imipenem-resistant P.aeruginosa identified from clinic were retrospectively analyzed. RESULTS Totally 128 strains of imipenem-resistant P.aeruginosa were isolated from the intensive care unit(60.9%),department of encephalopathy(21.9%),oncology department(8.6%).Source of P.aeruginosa mainly came from phlegmy(60.2%),pyorrhea(12.5%),secretion(12.5%).Drug resistance rate of imipenem-resistant P.aeruginosa to polymyxin B can achieve 0,compared to 40.63% and 46.09% to ceftazidime and amikacin.The drug resistance rate80.0% included sulphamethoxazole/trimethoprim,cefotaxime meropenem,aztreonam,ciprofloxacin,gentamicin and levofloxacin.The drug resistance rate50.0% included piperacillin,sulbactan/cefoperazone,piperacillin/tazobactam. CONCLUSION Imipenem-resistant P.aeruginosa isolates are multi-drug resistant.It is important to control bacterial resistance and prevent the spreading of imipenem-resistant P.aeruginosa.